Oral GLP-1 Medicines: What Is FDA-Approved, What Is Compounded, and How to Tell Them Apart

Quick answer

As of September 2026, three FDA-approved oral GLP-1 medicines exist: semaglutide tablets sold as Rybelsus and Ozempic tablets for adults with type 2 diabetes, Wegovy tablets for long-term weight reduction and cardiovascular risk reduction in adults, and Foundayo (orforglipron), approved on April 1, 2026, for long-term weight reduction in adults. There are also compounded oral and sublingual preparations, which are a different category with a different regulatory status. Much of the confusion about "GLP-1 pills" comes from running the two categories together.

The route does not decide the status. A compounded tablet or drop is no more FDA-approved than a compounded injection, and no oral form of tirzepatide has been approved at all.

Which oral GLP-1 medicines are FDA-approved, and for what?

Two public records settle which products are approved: Drugs@FDA, which lists application numbers and approval dates, and DailyMed, the National Library of Medicine's repository of approved labeling. For oral GLP-1 medicines they show three approved products.

Each approved tablet is swallowed whole; none is labeled to be held under the tongue. A few other label details are easy to miss:

• Ozempic is now two things. The Ozempic name was first approved as an injection in 2017 under a separate application, NDA 209637. NDA 213051, first approved for Rybelsus in 2019, now also lists Ozempic tablets. The label (effective January 30, 2026) says the two tablet brands are not substitutable strength for strength.
• One Wegovy label covers two forms. The Wegovy label (effective June 18, 2026) covers the injection and the tablets. The indications for adolescents aged 12 and older and for the liver condition MASH belong to the injection only.
• Adults only, by label. The Rybelsus and Ozempic tablets label and the Foundayo label (effective July 29, 2026) both state that safety and effectiveness have not been established in pediatric patients.
• Not combined with another GLP-1. The Wegovy and Foundayo labels each carry a Limitation of Use: using them together with another GLP-1 receptor agonist is not recommended.
• The same boxed warning. All three labels carry a boxed warning on the risk of thyroid C-cell tumors and are contraindicated in people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2. Foundayo's version explains that the rodent tumors were seen with other drugs in the class, that orforglipron is not pharmacologically active in rats or mice, and that human relevance has not been determined. The guide to orforglipron side effects walks through its label warnings and adverse reactions in depth.

No oral tirzepatide is approved. Drugs@FDA lists every approved tirzepatide product, sold as Mounjaro and Zepbound, as a solution for subcutaneous injection, and the Zepbound label is headed "Injection, for subcutaneous use." Whether an oral tirzepatide exists walks through the record and the products sold under that name, and what the evidence shows on sublingual tirzepatide covers drops held under the tongue.

Why does a peptide pill need an absorption enhancer?

Semaglutide is a peptide. Its label describes a "peptide backbone" that "is produced by yeast fermentation," with a molecular weight of 4113.58 g/mol, more than four times that of orforglipron calcium. Digestive enzymes break peptides down, so a peptide swallowed on its own struggles to reach the bloodstream intact. A 2026 review in Frontiers in Pharmacology frames the difference this way: small-molecule GLP-1 agonists "evade enzymatic degradation," while oral semaglutide relies on SNAC-mediated absorption "with stringent dosing requirements."

SNAC is salcaprozate sodium, an inactive ingredient listed for every approved semaglutide tablet. The label's clinical pharmacology section is direct about its role: the tablets "are co-formulated with SNAC which facilitates the absorption of semaglutide after oral administration. The absorption of semaglutide predominantly occurs in the stomach." A 2019 review in Pharmaceutics describes the mechanism researchers have proposed for SNAC with semaglutide as a "pH-elevating, monomer-inducing, and pepsin-inhibiting effect in the stomach."

That is where the strict routine comes from: an empty stomach, a small amount of plain water only, and a wait before eating, drinking or taking other oral medicines, each limit spelled out in the label. The label ties those instructions to its clinical pharmacology section, which reports that semaglutide absorption was higher with less water and after a longer fast following the dose.

Orforglipron takes a different approach: it is a small molecule rather than a peptide. The Foundayo label gives a molecular weight of 902.0 g/mol for orforglipron calcium, its inactive ingredients list no SNAC, and its clinical pharmacology section states: "No clinically relevant food effect on orforglipron exposure was observed." Its administration section says to take it "once daily, with or without food." Its label instead lists interactions with some medicines that strongly inhibit or induce the enzyme CYP3A4.

What this means for compounded forms. The approved semaglutide tablets behave as their labels describe because of one specific formulation, tested in the trials each label summarizes. A compounded tablet, capsule or drop has no approved label, so nothing in these labels, including their absorption data and their administration rules, can be assumed to apply to it.

What are the three things sold as "oral GLP-1"?

An approved oral tablet. Rybelsus, Ozempic tablets, Wegovy tablets and Foundayo were each reviewed and approved as finished products by FDA. Their labeling is public in DailyMed, and each has an application number you can look up in Drugs@FDA. Approved means the specific formulation, strength and manufacturer went through review. It does not mean the product is right for any particular person, which is a separate clinical question.

A compounded oral or sublingual preparation. Compounding is a pharmacy preparing a medication for an individual patient against a prescription. A compounded preparation is not FDA-approved as a finished product, is not a generic of any brand, and is not interchangeable with one. That is true of a compounded injection as much as a compounded tablet or drop. The route the medication takes does not change its regulatory status.

Something sold without a prescription. Anything offering semaglutide or tirzepatide with no clinician involved is not either of the above. Two questions settle it quickly: who wrote the prescription, and which licensed pharmacy filled it.

The practical consequence is that "is it a pill or a shot" tells you almost nothing about whether a product is legitimate, while "who prescribed it and who compounded it" tells you nearly everything. Those two questions also sort the products worn on the skin, and the guide to telling a medicine from a wellness patch turns them into a checklist anyone can run on a listing.

What does "not FDA-approved" mean for a compounded preparation?

It does not mean illegal. Compounding is a long-established, lawful part of pharmacy practice. Section 503A of the Federal Food, Drug, and Cosmetic Act covers a drug product "compounded for an identified individual patient based on the receipt of a valid prescription order," and requires the bulk ingredients to meet an applicable United States Pharmacopeia or National Formulary monograph where one exists. The statute applies to compounding by a licensed pharmacist in a state-licensed pharmacy, or by a licensed physician.

It does mean the finished preparation has not been through FDA premarket review. FDA puts it in one sentence: "compounded drugs are not FDA approved. This means the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed." There is no approved labeling for them. So when somebody quotes a precise figure for a compounded oral or sublingual preparation, the reasonable next question is where that figure came from, because it did not come from an approved label.

The statute also limits how often a pharmacy may compound what it calls "essentially copies of a commercially available drug product." In an update dated April 1, 2026, FDA reminded compounders of those conditions and noted that "Tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA's drug shortage list." That matters because, as the same update explains, an outsourcing facility may compound from bulk ingredients only when the substance is on that bulks list or the drug is on the shortage list.

What happened to a compounded GLP-1 pill in 2026?

This is a matter of public record rather than interpretation, and it is easy to check. In date order:

1. December 22, 2025. FDA approved Wegovy tablets under NDA 218316, according to Drugs@FDA.
2. Early February 2026. Hims & Hers announced a compounded semaglutide pill. Coverage at the time from Clinical Advisor and The Cardiology Advisor reported that Novo Nordisk objected publicly and said it would take legal and regulatory action.
3. February 6, 2026. FDA announced its intent to restrict GLP-1 active ingredients intended for non-FDA-approved compounded drugs that are being mass-marketed, naming Hims & Hers in the statement. The same statement addressed marketing claims that present compounded products as matching approved drugs, and listed seizure and injunction among the possible consequences.
4. February 7, 2026. Hims & Hers said in a statement on X that it had "decided to stop offering access" to the pill, as reported by BioPharma Dive and PharmExec. BioPharma Dive also reported that the Department of Health and Human Services referred the company to the Department of Justice to investigate potential violations of the Federal Food, Drug, and Cosmetic Act, and that Novo Nordisk filed a patent lawsuit.
5. April 1, 2026. FDA's compounding update confirmed that neither semaglutide nor tirzepatide was on the 503B bulks list or the drug shortage list.

We are not going to characterize any company's internal reasoning, because we do not have it. What the record supports is narrower and still useful: the pill was offered, and then it was withdrawn. If you are reading an article or a forum post from earlier in the year that recommends it, the recommendation has outlived the product.

How can you tell the three categories apart?

Each category leaves a different paper trail, and a reader can check every item.

An approved tablet has:

• a brand name and manufacturer that match a DailyMed label, such as Novo Nordisk for Rybelsus, Ozempic tablets and Wegovy tablets, or Eli Lilly for Foundayo;
• an application number (NDA 213051, 218316 or 220934) that Drugs@FDA lists as a tablet for oral use;
• a manufacturer's expiration date, which federal manufacturing rules require on a finished drug product, and a pharmacy that dispenses it against a prescription.

A compounded preparation has:

• a pharmacy label for a preparation made for you, because 503A compounding is done for an identified individual patient;
• a beyond-use date assigned by the pharmacy, which California's pharmacy regulations, for example, define as the date after which the preparation may not be dispensed or begin to be administered;
• a named pharmacy whose license you can confirm with your state board of pharmacy, and a named prescriber.

Something in the third category has none of the above. FDA's own list of telehealth red flags includes a company that "does not require a screening and prescription by a licensed doctor before providing medicine," prices that seem too good to be true, spelling errors on the label, and incorrect pharmacy addresses. FDA also reports fraudulent compounded products whose labels name pharmacies that do not exist.

A product that claims to be an approved drop or dissolving strip fails the first test outright: no approved oral GLP-1 is labeled for use under the tongue.

Why does this category keep attracting claims?

Injections put people off. That is a real preference and not an irrational one, so a form that removes the needle is genuinely attractive, and attractive categories attract claims. The pattern to watch for is a specific number attached to a preparation that has no approved labeling: an amount absorbed, a conversion to some injected dose, a potency comparison.

Because no approved label covers a compounded oral or sublingual preparation, this page gives no absorption or potency figures for one.

What should you ask about any non-injection form?

• Which pharmacy compounds it, and is that pharmacy licensed in your state. You can check with the state board of pharmacy directly.
• Is it compounded for you against a prescription, or shipped from stock. Patient-specific compounding is what a 503A pharmacy does.
• What is the beyond-use date, and how is it stored. Compounded preparations carry a pharmacy-assigned beyond-use date rather than a manufacturer expiration date.
• Who decides whether treatment is appropriate. A licensed clinician reviewing your history is a different thing from a questionnaire that approves everyone.
• What happens if you want to stop. Cancellation terms are a legitimacy signal in this category, not a detail.

Where to read more

• Oral tirzepatide: is there a tirzepatide pill?
• Sublingual tirzepatide: what the evidence shows
• Orforglipron side effects, from the published label
• Weight loss patches: telling a medicine from a wellness product

This article is for informational purposes only and does not constitute medical advice. Compounded medications are not FDA-approved as final products and are not generic versions of, equivalent to, or interchangeable with any brand-name medication. Medication is prescribed only if a licensed physician determines it is appropriate.

For the separate question of Rybelsus and weight management, see what the current Rybelsus label and research say.

Telehealth prescribing rules differ by state. Read the state-by-state guide.